Irina Niță1,2, Cornelia Nițipir1,2, Ștefania Andreea Toma3, Alexandra Maria Limbău4, Edvina Pîrvu5, Ioana Anca Bădărău1, Ioana Suciu6, George Suciu6, Loredana Sabina Cornelia Manolescu1. 1. Department of Microbiology, Parasitology and Virology, Faculty of Medicine, Midwifery and Nursing, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. 2. Medical Oncology Department, Elias University Emergency Hospital, 011461 Bucharest, Romania. 3. Medical Oncology Department, Ponderas Academic Hospital, 014142 Bucharest, Romania. 4. Dermatology Department, Municipal Hospital Curtea de Argeș, 115300 Curtea de Argeș, Romania. 5. Medical Oncology Department, Clinical Hospital "Colţea", 030167 Bucharest, Romania. 6. R&D Department, BEIA Consult International, 010158 Bucharest, Romania.
Abstract
BACKGROUND: We investigated the correlation between the androgen receptor (AR) and immunohistochemistry (IHC) as a prognostic factor in breast cancer (BC). AR is expressed in 60-80% of BC. METHODS: We evaluated the prognostic values of AR expression among 143 patients with BC for 36 months. The protocol was amended to measure androgen, estrogen and progesterone receptor expression by IHC and the percentage of hormone positive nuclei was quantified. We determined and quantified the Her2/neu status using IHC and in situ hybridization. The methodology consisted in using a Kaplan-Meier analysis and restricted mean survival time up to 36 months. The principal endpoints of the study were overall survival (OS) and progression free survival (PFS). RESULTS: 57% of patients (n = 82) from our group had AR+ (≥ 1%). Patients with AR+ had better OS, 35.50 vs. 33.40 months, with p = 0.027. Moreover, PFS was prolonged for patients AR+, 32.60 vs. 30.50 months, with p = 0.38. Triple negative breast cancer (TNBC) patients had lower OS and no difference was observed for PFS. CONCLUSIONS: Both OS and PFS were favorably influenced by the presence of AR. TNBC had worse outcomes compared with patients with hormonal or/and Her 2/neu positive disease in terms of OS.
BACKGROUND: We investigated the correlation between the androgen receptor (AR) and immunohistochemistry (IHC) as a prognostic factor in breast cancer (BC). AR is expressed in 60-80% of BC. METHODS: We evaluated the prognostic values of AR expression among 143 patients with BC for 36 months. The protocol was amended to measure androgen, estrogen and progesterone receptor expression by IHC and the percentage of hormone positive nuclei was quantified. We determined and quantified the Her2/neu status using IHC and in situ hybridization. The methodology consisted in using a Kaplan-Meier analysis and restricted mean survival time up to 36 months. The principal endpoints of the study were overall survival (OS) and progression free survival (PFS). RESULTS: 57% of patients (n = 82) from our group had AR+ (≥ 1%). Patients with AR+ had better OS, 35.50 vs. 33.40 months, with p = 0.027. Moreover, PFS was prolonged for patientsAR+, 32.60 vs. 30.50 months, with p = 0.38. Triple negative breast cancer (TNBC) patients had lower OS and no difference was observed for PFS. CONCLUSIONS: Both OS and PFS were favorably influenced by the presence of AR. TNBC had worse outcomes compared with patients with hormonal or/and Her 2/neu positive disease in terms of OS.
Authors: Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak Journal: Sex Med Rev Date: 2018-11-30
Authors: Farid Moinfar; Murat Okcu; Oleksiy Tsybrovskyy; Peter Regitnig; Sigurd F Lax; Wolfgang Weybora; Manfred Ratschek; Fattaneh A Tavassoli; Helmut Denk Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Ayca Gucalp; Sara Tolaney; Steven J Isakoff; James N Ingle; Minetta C Liu; Lisa A Carey; Kimberly Blackwell; Hope Rugo; Lisle Nabell; Andres Forero; Vered Stearns; Ashley S Doane; Michael Danso; Mary Ellen Moynahan; Lamia F Momen; Joseph M Gonzalez; Arooj Akhtar; Dilip D Giri; Sujata Patil; Kimberly N Feigin; Clifford A Hudis; Tiffany A Traina Journal: Clin Cancer Res Date: 2013-08-21 Impact factor: 12.531
Authors: Laura C Collins; Kimberly S Cole; Jonathan D Marotti; Rong Hu; Stuart J Schnitt; Rulla M Tamimi Journal: Mod Pathol Date: 2011-05-06 Impact factor: 7.842
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Dawn R Cochrane; Sebastián Bernales; Britta M Jacobsen; Diana M Cittelly; Erin N Howe; Nicholas C D'Amato; Nicole S Spoelstra; Susan M Edgerton; Annie Jean; Javier Guerrero; Francisco Gómez; Satyanarayana Medicherla; Iván E Alfaro; Emma McCullagh; Paul Jedlicka; Kathleen C Torkko; Ann D Thor; Anthony D Elias; Andrew A Protter; Jennifer K Richer Journal: Breast Cancer Res Date: 2014-01-22 Impact factor: 6.466
Authors: Mihaela C Radu; Calin Boeru; Melania-Elena Pop-Tudose; Andrei Necsulescu; Anca Dumitrescu; Claudia F Iancu; Irina Nita; Alexandra M Limbau; Corneliu Zaharia Journal: Cureus Date: 2021-06-01